PMID- 23860612
OWN - NLM
STAT- MEDLINE
DCOM- 20140602
LR  - 20200206
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 24
IP  - 11
DP  - 2013 Nov
TI  - Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ 
      cell tumors: long-term efficacy and safety outcomes.
PG  - 2887-92
LID - 10.1093/annonc/mdt271 [doi]
AB  - BACKGROUND: Since 1985, we introduced a modified combination of etoposide, 
      ifosfamide, and cisplatin (PEI) as second-line therapy of adult male germ cell 
      tumors with the aim to reduce toxic effect while maintaining efficacy over the 
      original regimen. PATIENTS AND METHODS: Patients received four cycles of 
      ifosfamide at 2.5 g/m(2) on days 1-2, etoposide, and cisplatin at 100 and 33 
      mg/m(2), respectively, on days 3-5 every 21 days, followed by surgery. Results 
      were stratified according to the International Germ Cell Consensus Classification 
      Group-2 (IGCCCG-2). RESULTS: From February 1985 to January 2012, 189 patients 
      were treated. 72.6% were IGCCCG-2 intermediate-to-very high risk. Thirty-five 
      patients (18.5%) had a complete response, 67 (35.4%) a marker normalization 
      (PRm-). Median follow-up was 122.1 months (inter-quartile range [IQR]: 
      71.4-232.0). Two-year progression-free and 5-year overall survival were 34.3% 
      [95% confidence interval (CI) 28.1% to 41.9%] and 42.1% (95% CI 35.3% to 50.2%), 
      respectively. Survival estimates compared favorably with those obtained by 
      conventional dose chemotherapy (CDCT) regimens in each prognostic category. 70.4% 
      of grade 3-4 neutropenia (25.5% febrile neutropenia), 48.1% thrombocytopenia, 
      21.2% anemia, 3.2% neurotoxic effect, and no severe renal toxic effect were 
      recorded. CONCLUSION: Dose-modified Italian PEI should be considered as an 
      appropriate benchmark for CDCT in the first salvage setting.
FAU - Necchi, A
AU  - Necchi A
AD  - Departments of Medical Oncology.
FAU - Nicolai, N
AU  - Nicolai N
FAU - Mariani, L
AU  - Mariani L
FAU - Raggi, D
AU  - Raggi D
FAU - Fare, E
AU  - Fare E
FAU - Giannatempo, P
AU  - Giannatempo P
FAU - Catanzaro, M
AU  - Catanzaro M
FAU - Biasoni, D
AU  - Biasoni D
FAU - Torelli, T
AU  - Torelli T
FAU - Stagni, S
AU  - Stagni S
FAU - Milani, A
AU  - Milani A
FAU - Piva, L
AU  - Piva L
FAU - Pizzocaro, G
AU  - Pizzocaro G
FAU - Gianni, A M
AU  - Gianni AM
FAU - Salvioni, R
AU  - Salvioni R
LA  - eng
PT  - Journal Article
DEP - 20130716
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - Q20Q21Q62J (Cisplatin)
RN  - UM20QQM95Y (Ifosfamide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Cisplatin/*administration & dosage
MH  - Disease-Free Survival
MH  - Drug-Related Side Effects and Adverse Reactions/classification/pathology
MH  - Etoposide/*administration & dosage
MH  - Humans
MH  - Ifosfamide/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Neoplasms, Germ Cell and Embryonal/*drug therapy/pathology
MH  - Prognosis
MH  - Remission Induction
MH  - Salvage Therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - combination chemotherapy
OT  - salvage therapies
OT  - testicular neoplasms
EDAT- 2013/07/19 06:00
MHDA- 2014/06/03 06:00
CRDT- 2013/07/18 06:00
PHST- 2013/07/18 06:00 [entrez]
PHST- 2013/07/19 06:00 [pubmed]
PHST- 2014/06/03 06:00 [medline]
AID - S0923-7534(19)37344-2 [pii]
AID - 10.1093/annonc/mdt271 [doi]
PST - ppublish
SO  - Ann Oncol. 2013 Nov;24(11):2887-92. doi: 10.1093/annonc/mdt271. Epub 2013 Jul 16.